By otakuyassine3@gmail.com 
TransMedics Group, Inc. (NASDAQ:TMDX – Get Free Report)’s stock price was down 4.4% during trading on Wednesday . The company traded as low as $62.80 and last traded at $62.80. Approximately 598,790 shares were traded during mid-day trading, a decline of 43% from the average daily volume of 1,047,481 shares. The stock had previously closed at $65.71.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on TMDX shares. TD Cowen decreased their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 price target (down from $116.00) on shares of TransMedics Group in a research note on Tuesday. Canaccord Genuity Group cut their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Piper Sandler lowered their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. Finally, Robert W. Baird dropped their price objective on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.
Check Out Our Latest Research Report on TMDX
TransMedics Group Stock Performance
The business has a fifty day moving average of $89.89 and a 200 day moving average of $129.32. The company has a market cap of $2.07 billion, a P/E ratio of 65.64 and a beta of 2.06. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.
TransMedics Group (NASDAQ:TMDX – Get Free Report) last released its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. During the same period in the previous year, the company earned ($0.12) earnings per share. TransMedics Group’s quarterly revenue was up 63.7% on a year-over-year basis. On average, equities analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.
Insider Activity
In related news, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the sale, the director now owns 732 shares of the company’s stock, valued at $61,158.60. The trade was a 90.22 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total value of $438,493.92. Following the sale, the insider now owns 20,843 shares of the company’s stock, valued at approximately $3,089,766.32. This represents a 12.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 19,417 shares of company stock worth $2,240,738. Insiders own 7.00% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of TMDX. Driehaus Capital Management LLC boosted its position in shares of TransMedics Group by 15.8% in the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after purchasing an additional 202,867 shares during the period. Geode Capital Management LLC grew its position in shares of TransMedics Group by 1.3% during the third quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock worth $119,938,000 after purchasing an additional 10,106 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in TransMedics Group by 5.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock valued at $94,061,000 after purchasing an additional 30,092 shares during the period. Vaughan Nelson Investment Management L.P. boosted its stake in TransMedics Group by 24.3% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock worth $51,654,000 after purchasing an additional 64,360 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in TransMedics Group by 2.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock valued at $42,656,000 after buying an additional 6,634 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.
About TransMedics Group
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
See Also
Receive News & Ratings for TransMedics Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for TransMedics Group and related companies with MarketBeat.com’s FREE daily email newsletter.